DOW JONES NEWSWIRES Danish biotech company Genmab A/S (GEN.KO) said Monday it has entered an agreement with Swiss pharmaceutical company Novartis AG (NOVN.VX) to use its DuoBody technology platform to develop new antibodies. MAIN FACTS: -Under the agreement, Genmab receives an upfront payment of $2 million. -If all milestones in the agreement are achieved, the total potential value of the agreement to Genmab would be around $175 million, plus research funding and royalties. -The agreement is not expected to have a material impact on Genmab's 2012 financial guidance. -Genmab will create panels of bispecific antibodies to two disease target combinations identified by Novartis. -All research work on the programs is fully funded by Novartis. -Shares in Genmab closed Friday at DKK41.50. Write to Gustav Sandstrom at gustav.sandstrom@dowjones.com
